帕金森病的治疗：过去、现在和未来。
Parkinson's disease treatment: past, present, and future.
机构信息
Yale University School of Medicine, New Haven, CT, 06511, USA.
出版信息
J Neural Transm (Vienna). 2020 May;127(5):785-791. doi: 10.1007/s00702-020-02167-1. Epub 2020 Mar 14.
Abstract
The substantial contributions of Dr. Gerald Stern to past and current treatments for Parkinson's disease patients are reviewed, which form the foundation for an evaluation of future options to control symptoms and halt progression of the disease. These opportunities will depend on a greater understanding of the relative contributions of the environment, genetic and epigenetic influences to disease onset, and promise to emerge as strategies for improving mitochondrial function, halting accumulation of synuclein and neuromelanin, in addition to refinement of stem cell and gene therapies. Such advances will be achieved through deployment of improved models for the disease.
摘要
回顾了杰拉尔德·斯特恩博士（Gerald Stern）对过去和当前帕金森病患者治疗方法的重大贡献，这些贡献为评估控制症状和阻止疾病进展的未来选择奠定了基础。这些机会将取决于对环境、遗传和表观遗传因素对疾病发病的相对贡献的更深入了解，并有望成为改善线粒体功能、阻止突触核蛋白和神经黑色素积累的策略，此外还将改进干细胞和基因治疗。通过部署更好的疾病模型，将实现这些进展。
相似文献
1
Parkinson's disease treatment: past, present, and future.帕金森病的治疗：过去、现在和未来。
J Neural Transm (Vienna). 2020 May;127(5):785-791. doi: 10.1007/s00702-020-02167-1. Epub 2020 Mar 14.
2
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.左旋多巴治疗的四位先驱：阿尔维德·卡尔松、奥莱赫·霍尼基维茨、乔治·科齐亚斯和梅尔文·亚尔。
Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8.
3
Impact Commentaries. A modern perspective on the top 100 cited JNNP papers of all time: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease: accuracy of clinical diagnosis of idiopathic Parkinson's disease.影响评论。关于有史以来被引用次数最多的100篇《神经病学、神经外科学与精神病学杂志》论文的现代视角：路易体与特发性帕金森病发病机制的相关性：特发性帕金森病临床诊断的准确性。
J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):954-5. doi: 10.1136/jnnp-2012-302969. Epub 2012 May 29.
4
Revolutionizing our understanding of Parkinson's disease: Dr. Heinz Reichmann's pioneering research and future research direction.颠覆帕金森病认知的革命：海因茨·赖希曼博士的开拓性研究与未来研究方向。
J Neural Transm (Vienna). 2024 Dec;131(12):1367-1387. doi: 10.1007/s00702-024-02812-z. Epub 2024 Aug 7.
5
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.帕金森病的过去、现在和未来：震颤麻痹 200 周年专论。
Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115.
6
Parkinson's disease: 10 years of progress, 1997-2007.帕金森病：1997-2007 年十年进展
Mov Disord. 2010;25 Suppl 1:S2-14. doi: 10.1002/mds.22796.
7
Possible therapies of Parkinson's disease: A review.帕金森病的可能治疗方法：综述。
J Clin Neurosci. 2020 May;75:1-4. doi: 10.1016/j.jocn.2020.03.024. Epub 2020 Apr 1.
8
Chapter 33: the history of movement disorders.第33章：运动障碍病史。
Handb Clin Neurol. 2010;95:501-46. doi: 10.1016/S0072-9752(08)02133-7.
9
Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.GBA 相关帕金森病的进展——病理学、临床表现与治疗
Neurochem Int. 2016 Feb;93:6-25. doi: 10.1016/j.neuint.2015.12.004. Epub 2015 Dec 30.
10
The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.帕金森病中靶向基因治疗策略和生物标志物的未来。
Biomolecules. 2020 Jun 16;10(6):912. doi: 10.3390/biom10060912.
引用本文的文献
1
Evaluating the Utility of Wearable Sensors for the Early Diagnosis of Parkinson Disease: Systematic Review.评估可穿戴传感器在帕金森病早期诊断中的效用：系统评价
J Med Internet Res. 2025 Jul 21;27:e69422. doi: 10.2196/69422.
2
The Role of Inflammation in Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis.炎症在神经退行性疾病中的作用：帕金森病、阿尔茨海默病和多发性硬化症。
Int J Mol Sci. 2025 May 28;26(11):5177. doi: 10.3390/ijms26115177.
3
Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism.大麻二酚在利血平诱导的帕金森病进行性模型中的预防性有益作用。
Front Pharmacol. 2025 May 8;16:1539783. doi: 10.3389/fphar.2025.1539783. eCollection 2025.
4
Identifying Key Plasma Proteins in the Onset of Parkinson's Disease: Proteome-Wide Mendelian Randomization and Single-Cell RNA Sequencing Analysis.识别帕金森病发病过程中的关键血浆蛋白：全蛋白质组孟德尔随机化和单细胞RNA测序分析
Mol Neurobiol. 2025 May 16. doi: 10.1007/s12035-025-05041-x.
5
Nanobiosensors in neurodegenerative disease diagnosis: A promising pathway for early detection.用于神经退行性疾病诊断的纳米生物传感器：早期检测的一条有前景的途径。
Digit Health. 2025 May 14;11:20552076251342457. doi: 10.1177/20552076251342457. eCollection 2025 Jan-Dec.
6
Management of freezing of gait - mechanism-based practical recommendations.步态冻结的管理——基于机制的实用建议
Nat Rev Neurol. 2025 Apr 1. doi: 10.1038/s41582-025-01079-6.
7
Corydaline Alleviates 1-Methyl-4-Phenylpyridium (MPP)-Induced Human Neuroblastoma Cell Injury by BAP1-NRF2/HO-1/GPX4 Pathway.紫堇碱通过BAP1-NRF2/HO-1/GPX4通路减轻1-甲基-4-苯基吡啶（MPP）诱导的人神经母细胞瘤细胞损伤。
Neurochem Res. 2025 Feb 27;50(2):107. doi: 10.1007/s11064-025-04351-9.
8
The Role of Virtual Reality in Postural Rehabilitation for Patients with Parkinson's Disease: A Scoping Review.虚拟现实在帕金森病患者姿势康复中的作用：一项范围综述
Brain Sci. 2024 Dec 29;15(1):23. doi: 10.3390/brainsci15010023.
9
Potential Biomarkers and Treatment of Neuroinflammation in Parkinson's Disease.帕金森病中神经炎症的潜在生物标志物与治疗
Actas Esp Psiquiatr. 2025 Jan;53(1):181-188. doi: 10.62641/aep.v53i1.1779.
10
Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson's Disease and Frailty.营养保健品突破极限：展望帕金森病与身体虚弱问题
Int J Mol Sci. 2024 Dec 26;26(1):122. doi: 10.3390/ijms26010122.
本文引用的文献
1
Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism.吡格列酮激活大脑中的对氧磷酶 2：一种新的神经保护机制。
Exp Neurol. 2020 May;327:113234. doi: 10.1016/j.expneurol.2020.113234. Epub 2020 Feb 7.
2
Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.类器官和多能干细胞在帕金森病模型中的应用：专家对其在药物发现中的价值的看法。
Expert Opin Drug Discov. 2020 Apr;15(4):427-441. doi: 10.1080/17460441.2020.1703671. Epub 2020 Jan 3.
3
Common genetic variants associated with Parkinson's disease display widespread signature of epigenetic plasticity.常见的帕金森病相关遗传变异显示出广泛的表观遗传可塑性特征。
Sci Rep. 2019 Dec 5;9(1):18464. doi: 10.1038/s41598-019-54865-w.
4
Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis.帕金森病中的肠道信号：微生物群-肠-脑轴
Mov Disord Clin Pract. 2019 Oct 23;6(8):639-651. doi: 10.1002/mdc3.12840. eCollection 2019 Nov.
5
Three-dimensional modeling of human neurodegeneration: brain organoids coming of age.人类神经退行性疾病的三维建模：类脑器官趋于成熟。
Mol Psychiatry. 2020 Feb;25(2):254-274. doi: 10.1038/s41380-019-0500-7. Epub 2019 Aug 23.
6
Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease.神经黑色素、衰老与帕金森病中的神经元易损性。
Mov Disord. 2019 Oct;34(10):1440-1451. doi: 10.1002/mds.27776. Epub 2019 Jun 28.
7
α-Synuclein in Parkinson's disease: causal or bystander?α-突触核蛋白在帕金森病中的作用：是病因还是旁观者？
J Neural Transm (Vienna). 2019 Jul;126(7):815-840. doi: 10.1007/s00702-019-02025-9. Epub 2019 Jun 25.
8
Gene-targeting approaches for movement disorders: recent advances.基因靶向治疗运动障碍疾病：最新进展。
Curr Opin Neurol. 2019 Aug;32(4):566-570. doi: 10.1097/WCO.0000000000000719.
9
Human-Monkey Chimeras for Modeling Human Disease: Opportunities and Challenges.用于人类疾病建模的人猴嵌合体：机遇与挑战
Methods Mol Biol. 2019;2005:221-231. doi: 10.1007/978-1-4939-9524-0_15.
10
PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.过氧化物酶体增殖物激活受体-γ 激动剂吡格列酮可减少帕金森病 6-羟多巴胺模型中黑质的小胶质细胞增殖和 NF-κB 激活。
Pharmacol Rep. 2019 Aug;71(4):556-564. doi: 10.1016/j.pharep.2018.11.005. Epub 2018 Nov 30.
Zotero 插件